Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

Davidson, Michael; Madelenat, P.; Stein, Evan A.; Gotto, Antonio M.; Raza, Ali; Chitra, Rohini; Hutchinson, Howard G.

doi:10.1016/s0002-9149(01)02226-3

Cited by 219 publications

(119 citation statements)

References 23 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…19 Davidson et al, in the study of 516 North American population found that Rosuvastatin 5mg/day in compared to Atorvastatin 10mg/day were associated with greater in LDL-C, reduction and HDL-C increase which is similar with the result of my study. 20 Reduction in the TC and TG did not match with result of my study of 3 months periods. The possible explanation for this conflicting result may be that, patients in my study did not have any dietary run-in before the drug therapy.…”

Section: Discussioncontrasting

confidence: 54%

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Thapa¹,

Rai²,

Mahara³

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

INTRODUCTIONWorldwide, hypercholesterolemia cause about 56% of ischemic heart disease and 18% of strokes, resulting to 4.4 million deaths annually. Hyperlipidemia and the rates of hypercholesterolemia (total cholesterol ≥201.1mg/dl) increased from 18% to 31% in adults aged 35-59. 1 Studies have shown that the risk of ischemic heart disease in individuals with hypercholesterolemia is about thrice as great as in those with normal plasma cholesterol level indicating that reduction in plasma cholesterol does reduce the risk of myocardial infraction. 2There is increasing evidence that Hyperlipidemia is a major cause of atherosclerosis and atherosclerosisassociated conditions, such as coronary heart disease (CHD), ischemic cerebrovascular disease and peripheral vascular disease and reduction of TC and LDL-C below 442.86mg/dl and 116mg/dl, respectively, lowers the incidence of CHD. The lifetime risk of developing CHD after 40 years of age is 49% in men and 32% in women. Even at 70 years of age, the risk is 35% for men and 24% for women. 3 The lifetime risk of developing CVD at 50 years of age is estimated to be 1 in 2 for men and 2 in 5 for women in USA only. 4 Numerous epidemiologic investigations have suggested that age, sex, elevated LDL-ABSTRACT Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslipidemia.Methods: This open-label, randomized, parallel group, comparative, prospective study of six months duration included 100 patients. The age group of patients varied from 30 to 69 years with dyslipidemia. Patients were divided in to 2 groups. 50 patients in group-1 received Atorvastatin 10mg once daily and 50 patients in group-2 received Rosuvastatin 5 mg once daily. The level of TC, TG, LDL, VLDL and HDL were assessed at baseline and at the end of 3 months and 6 months. Results: At 3 months, LDL was reduced significantly more with 5mg Rosuvastatin than with Atorvastatin 10 mg [43.68% vs. 40.74% (P 0.0049)]. At 6 months, Rosuvastatin 5mg reduced LDL significantly more than Atorvastatin 10 mg [48.69% vs. 43.85% (P 0.00)]. TC, HDL, TG and VLDL were more favourably modified by Rosuvastatin at 6 months (P <0.005). Reduction of total cholesterol levels in Rosuvastatin group was not statistically significant when compared with Atorvastatin group (P 0.103). Conclusions: Rosuvastatin 5mg was more efficacious than Atorvastatin 10mg for the improvement of lipid profile during the period of 6 months follow-up drug therapy in patients with dyslipidemia.

show abstract

Section: Discussioncontrasting

confidence: 54%

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Thapa¹,

Rai²,

Mahara³

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…28 In phase III studies of primary hypercholesterolemic patients, those receiving a 5-or 10-mg dose of rosuvastatin versus atorvastatin 10 mg showed greater reductions in LDL-C (40 and 43 vs. 35%, p < 0.01) and increases in HDL-C (13 and 12 vs. 8%, p < 0.05). 29 The same doses of rosuvastatin were also more efficacious in lowering LDL-C than 20 mg pravastatin and simvastatin. 30 In addition, new approaches to reduction of plasma LDL-C, are under development, 31 such as inhibitors of the intestinal bile acid transporter (iBAT), which promotes the intestinal reuptake of bile acids.…”

Section: New Developments In Lipid-modifying Therapymentioning

confidence: 98%

Therapy to reduce risk of coronary heart disease

Rader¹

2003

Clinical Cardiology

View full text Add to dashboard Cite

Summary: Recent primary and secondary intervention studies have shown that reduction of low-density lipoprotein cholesterol (LDL-C) with statins significantly reduced coronary heart disease (CHD) morbidity and mortality. However, many patients with dyslipidemia who have or are at risk for CHD do not reach target LDL-C goals. The recently updated National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines identify a group of patients at very high risk for CHD for more aggressive LDL-C reduction and reaffirm the importance of high-density lipoprotein cholesterol (HDL-C) by raising the categorical threshold to 40 mg/dl. Lipid-lowering therapy needs to be more aggressive in both primary and secondary prevention settings, and therapy should be considered to increase HDL-C as well as lower LDL-C in order to improve patient outcomes. Both combination therapy and the next generation of statins may provide improved efficacy across the dyslipidemia spectrum.

show abstract

“…It is used in the treatment of hypercholesterolemia and dyslipidemia [3][4]. Rosuvastatin is very effective in reducing low density lipoprotein cholesterol [5] and many studies have demonstrated its efficacy greater than other drugs of its class such as atorvastatin, simvastatin and pravastatin [5][6][7]. During literature review many methods were found reporting separation of rosuvastatin like capillary zone electrophoresis [8], Spectrophotometry [9][10] and HPLC [11][12][13][14].…”

Section: Rosuvastatin Figure (1) Is the Calcium Salt Of (E)-7-[4-(4-fmentioning

confidence: 99%

Lc Determination of Rosuvastatin and Ezetimibe in Human Plasma

Ashfaq

Ahmad

Khan

et al. 2013

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

A simple, precise, sensitive and validated reverse-phase high performance liquid chromatographic (RP-HPLC) method was developed for the simultaneous estimation of rosuvastatin and ezetimibe in human plasma. The method involved protein precipitation and extraction of both drugs from plasma using acetonitrile and then separation on a C-18 column. Both the analytes were detected at a wavelength of 240 nm using diode array detector. Mobile phase for the said separation consists of a mixture of 1.5% phosphoric acid and acetonitrile in 30:70, v/v ratio. Linearity was in the range of 0.32-267 mg/mL for rosuvastatin and 0.08-67 mg/mL for ezetimibe with coefficient of determination between 0.9997 and 0.9967. Limit of detection was 0.106 mg/mL for rosuvastatin and 0.026 mg/mL for ezetimibe whereas limit of quantification was 0.32 mg/mL and 0.08 mg/mL for rosuvastatin and ezetimibe respectively. Recovery of both the analytes was greater than 75% with RSD less than 15 %. The total run time was less than five min for the two components. The developed method can be fruitfully employed for the determination of these two drugs in human plasma. 1-INTRODUCTION-enoic acid and a competitive inhibitor of HMG-CoA reductase [1][2]. It is used in the treatment of hypercholesterolemia and dyslipidemia [3][4]. Rosuvastatin is very effective in reducing low density lipoprotein cholesterol [5] and many studies have demonstrated its efficacy greater than other drugs of its class such as atorvastatin, simvastatin and pravastatin [5][6][7]. During literature review many methods were found reporting separation of rosuvastatin like capillary zone electrophoresis [8], Spectrophotometry [9-10] and HPLC [11][12][13][14].formulations.We are currently engaged in the development of simple HPLC methods for the determination of binary combinations of different classes of drugs including antihyperlipidemic drugs [21,22,[36][37][38][39][40][41][42][43][44][45][46]. The present work was therefore planned to develop a simple HPLC method to determine rosuvastatin and ezetimibe simultaneously in human plasma. During this study, a simple, economic and sensitive HPLC method with run time less than five min was developed in human plasma. The developed method have superiority over the Varghese et al method in that its linear range is 0.32-267 mg/mL for rosuvastatin and 0.08-67 mg/mL for ezetimibe and also the method is applied for human plasma. The method could have the potential to be used for any sort of studies planned for conducting in human plasma. Literature survey also revealed some analytical methods for the simultaneous determination of rosuvastatin and ezetimibe. These include spectrophotometry [30][31], HPTLC [32], Micellar liquid chromatography [33] and simultaneous equation method [34]. Recently Varghese et al [35] reported an RP-HPLC method for the simultaneous determination of rosuvastatin and ezetimibe. The method has some limitations as its linear range were narrow and have high detection limits of 0.5µg/mL for both drugs. Secondly the ...

show abstract

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

Cited by 219 publications

References 23 publications

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Therapy to reduce risk of coronary heart disease

Lc Determination of Rosuvastatin and Ezetimibe in Human Plasma

Contact Info

Product

Resources

About